Journal article
Reversible Cabozantinib-Induced Cardiomyopathy
Abstract
Cabozantinib is a multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factor receptor, as well as MET, RET, and AXL. It is currently approved for treating advanced thyroid and kidney cancers, and is being investigated in other cancers. We present a case of reversible heart failure due to cabozantinib use in a 70-year-old man with metastatic renal cell carcinoma. This is, to our knowledge, one of the first …
Authors
Alhussein M; Hotte SJ; Leong DP
Journal
Canadian Journal of Cardiology, Vol. 35, No. 4, pp. 544.e1–544.e2
Publisher
Elsevier
Publication Date
April 2019
DOI
10.1016/j.cjca.2018.12.025
ISSN
0828-282X